(NASDAQ: ACHV) Achieve Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.8%.
Achieve Life Sciences's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast ACHV's revenue for 2026 to be $1,379,036,835, with the lowest ACHV revenue forecast at $1,031,698,380, and the highest ACHV revenue forecast at $1,726,375,289. On average, 1 Wall Street analysts forecast ACHV's revenue for 2027 to be $3,782,894,060, with the lowest ACHV revenue forecast at $3,782,894,060, and the highest ACHV revenue forecast at $3,782,894,060.
In 2028, ACHV is forecast to generate $8,253,587,040 in revenue, with the lowest revenue forecast at $8,253,587,040 and the highest revenue forecast at $8,253,587,040.